Literature DB >> 22957983

Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011.

W G John1.   

Abstract

The WHO was very clear that an HbA(1c) of 48 mmol/mol (6.5%) and above is diagnostic of diabetes. They were less clear regarding results that fell below 48 mmol/mol. The WHO recognize that individuals with HbA(1c) values below the cut-off point may still have diabetes, but give no guidance on how to investigate further. It is important that these individuals, who may be at increased risk of developing diabetes, are monitored correctly; a recommended scheme is given in Fig. 2; following these recommendations will ensure at-risk people are not overlooked and will be monitored closely. Even although it is not recommended to combine HbA(1c) with glucose measurement for diagnosis, the WHO did not discount the value of a fasting glucose and an oral glucose tolerance test to diagnose diabetes in selected individuals; it is the responsibility of the investigating doctor to choose how best to diagnose on an individual basis. This new method of diagnosing diabetes will identify a different cohort as having diabetes than is currently being diagnosed; but the process of investigation that does not require a fasting sample makes investigation easier, allowing more people to be investigated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957983     DOI: 10.1111/j.1464-5491.2012.03762.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  27 in total

Review 1.  The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review.

Authors:  Emma English; Iskandar Idris; Georgina Smith; Ketan Dhatariya; Eric S Kilpatrick; W Garry John
Journal:  Diabetologia       Date:  2015-05-21       Impact factor: 10.122

Review 2.  Evaluation of Performance of Laboratories and Manufacturers Within the Framework of the IFCC model for Quality Targets of HbA1c.

Authors:  Cas Weykamp; Carla Siebelder
Journal:  J Diabetes Sci Technol       Date:  2017-11-17

3.  Diabetes care in the dispersed population of Greenland. A new model based on continued monitoring, analysis and adjustment of initiatives taken.

Authors:  Michael Lynge Pedersen
Journal:  Int J Circumpolar Health       Date:  2019       Impact factor: 1.228

4.  Use of glycosylated haemoglobin as diagnostic tool in Greenland: prevalence of diagnosed diabetes mellitus.

Authors:  Line Damsgaard; Michael Lynge Pedersen
Journal:  Diabetol Metab Syndr       Date:  2013-10-09       Impact factor: 3.320

Review 5.  HbA1c: a review of analytical and clinical aspects.

Authors:  Cas Weykamp
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

Review 6.  The optimal cutoff value of glycated hemoglobin for detection of diabetic retinopathy.

Authors:  Jung Min Kim; Dong-Jun Kim
Journal:  Diabetes Metab J       Date:  2015-02       Impact factor: 5.376

7.  An investigation of the glucose monitoring practices of nurses in stroke care: a descriptive cohort study.

Authors:  Elizabeth Ann Laird; Vivien E Coates; Assumpta A Ryan; Mark O McCarron; Diane Lyttle; David Chaney
Journal:  Nurs Res Pract       Date:  2013-08-25

8.  Opportunistic pathology-based screening for diabetes.

Authors:  Aaron J Simpson; Renata Krowka; Jennifer L Kerrigan; Emma K Southcott; J Dennis Wilson; Julia M Potter; Christopher J Nolan; Peter E Hickman
Journal:  BMJ Open       Date:  2013-09-23       Impact factor: 2.692

Review 9.  Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes.

Authors:  Kamlesh Khunti; Hamidreza Mani; Felix Achana; Nicola Cooper; Laura J Gray; Melanie J Davies
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

Review 10.  HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?

Authors:  Bernd Kowall; Wolfgang Rathmann
Journal:  Diabetes Metab Syndr Obes       Date:  2013-11-29       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.